Referencias►
1.
Sengespeik HC, Zimmermann T, Peiske C, et al. Myrtol standardized in the treatment of acute and chronic respiratory infections in children. A multicenter post-marketing surveillance study.
Arzneimittelforschung. 1998;48:990-994.
2.
Federspil P, Wulkow R, Zimmermann T. Effects of standardized Myrtol in therapy of acute sinusitisâresults of a double-blind, randomized multicenter study compared with placebo.
Laryngorhinootologie. 1997;76:23-27.
3.
Behrbohm H, Kaschke O, Sydow K. Effect of the phytogenic secretolytic drug Gelomyrtol forte on mucociliary clearance of the maxillary sinus.
Laryngorhinootologie. 1995;74:733-737.
4.
Meister R, Wittig T, Beuscher N, et al. Efficacy and tolerability of Myrtol standardized in long-term treatment of chronic bronchitis. A double-blind, placebo-controlled study. Study Group Investigators.
Arzneimittelforschung. 1999;49:351-358.
5.
Matthys H, de Mey C, Carls C, et al. Efficacy and tolerability of Myrtol standardized in acute bronchitis. A multi-centre, randomised, double-blind, placebo-controlled parallel group clinical trial vs. cefuroxime and ambroxol.
Arzneimittelforschung. 2000;50:700-711.
6.
Ulmer WT, Schott D. Chronic obstructive bronchitis. Effect of Gelomyrtol forte in a placebo-controlled double-blind study.
Fortschr Med. 1991;109:547-550.
7.
Dorow P, Weiss T, Felix R, et al. Effect of a secretolytic and a combination of pinene, limonene and cineole on mucociliary clearance in patients with chronic obstructive pulmonary.
Arzneimittelforschung. 1987;37:1378-1381.
